AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg (PROBE trials)
Number of subjects: 860
Study 10877480 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary rest break schedule (includes two 15-min breaks and an additional 5-min break each hour)
Number of subjects: 42
Study 10877480 — intervention group
Group type: COMPARATOR
Intervention: Conventional rest break schedule (includes two 15-min breaks)
Number of subjects: 42
Study 10877480 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary rest break schedule
Number of subjects: 42
Study 10877480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 42
Study 9105068 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day
Number of subjects: 283
Study 9105068 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg twice a day
Number of subjects: 283
Study 9105068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 8252318 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 20
Study 8252318 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg daily
Number of subjects: 20
Study 8252318 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1500 mg daily
Number of subjects: 20
Study 8252318 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen combined with 4 g paracetamol daily
Number of subjects: 20
Study 8252318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower naproxen doses with paracetamol
Number of subjects: 20
Study 3515924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 182
Study 3515924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 182
Study 3515924 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac sodium 100 mg
Number of subjects: 182
Study 3515924 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine 650 mg + 60 mg
Number of subjects: 182
Study 3515924 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 182
Study 3515924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 31351444 — intervention group
Group type: EXPERIMENTAL
Intervention: Care manager function in collaborative care
Number of subjects: 40
Study 29116880 — intervention group
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Number of subjects: 101
Study 29116880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 26208120 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive remediation (CR)
Number of subjects: 25
Study 26208120 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive remediation (CR)
Number of subjects: 25
Study 21911650 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal gene therapy using recombinant adeno‐associated virus 2 (rAAV2) carrying the RPE65 gene
Number of subjects: 15
Study 21911650 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal gene therapy
Number of subjects: 15
Study 21911650 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 15
Study 20089951 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg orally twice daily)
Number of subjects: 3408
Study 20089951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study 20089951 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 3408
Study 17884802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB) with ropivacaine 10 mg ml(‐1)
Number of subjects: 42
Study 17884802 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline injection)
Number of subjects: 42
Study 15122134 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair
Number of subjects: 60
Study 15122134 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 60
Study 15122134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12202471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxylated vitamin D
Number of subjects: 25
Study 12202471 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard vitamin D
Number of subjects: 25
Study 12202471 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (both standard and hydroxylated)
Number of subjects: 25
Study 9661575 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg preoperatively and 8 mg.kg‐1.h‐1 intraoperatively
Number of subjects: 46
Study 9661575 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution
Number of subjects: 46
Study 8697927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (L)
Number of subjects: 72
Study 8697927 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (O)
Number of subjects: 72
Study 2792672 — intervention group
Group type: EXPERIMENTAL
Intervention: Garren‐Edwards gastric bubble (GEGB)
Number of subjects: 59
Study 2792672 — intervention group
Group type: COMPARATOR
Intervention: Sham insertion
Number of subjects: 59
Study 2792672 — intervention group
Group type: COMPARATOR
Intervention: Both groups (GEGB and sham)
Number of subjects: 59
Study 14659 — intervention group
Group type: EXPERIMENTAL
Intervention: medazepam
Number of subjects: 20
Study 14659 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 20
Study 14659 — intervention group
Group type: EXPERIMENTAL
Intervention: chlordiazepoxide
Number of subjects: 20
Study 14659 — intervention group
Group type: EXPERIMENTAL
Intervention: amylobarbitone
Number of subjects: 20
Study 14659 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29956034 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy (Habit reversal training and exposure response prevention)
Number of subjects: 59
Study 29956034 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (Habit reversal training and exposure response prevention)
Number of subjects: 59
Study 29956034 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (Individual and Group)
Number of subjects: 59
Study 27716668 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Medications (PIM) identified using the Priscus list
Number of subjects: 448
Study 27716668 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM prescription rates
Number of subjects: 448
Study 27716668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of a mental or behavioral disorder
Number of subjects: 448
Study 26947279 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7-TT
Number of subjects: 40
Study 26947279 — intervention group
Group type: COMPARATOR
Intervention: PNEUMO-23
Number of subjects: 40
Study 23057654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (TC) for 12 weeks
Number of subjects: 16
Study 23057654 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 16
Study 20505749 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 1320
Study 19639690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal electrophoresis using mexidol
Number of subjects: 0
Study 17910224 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide gel
Number of subjects: 13
Study 17910224 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide gel
Number of subjects: 13
Study 17910224 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 13
Study 15851743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime pergolide (1 mg)
Number of subjects: 22
Study 15851743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11805862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 x 30 min of stationary cycling at 70% of peak aerobic power for 9 weeks)
Number of subjects: 0
Study 11805862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 11805862 — intervention group
Group type: COMPARATOR
Intervention: Serotonin agonist (buspirone hydrochloride)
Number of subjects: 0
Study 11805862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10363422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT and ddl
Number of subjects: 28
Study 10363422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 28
Study 10363422 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 28
Study 10363422 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 8750367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month or 600 mg once a month)
Number of subjects: 180
Study 8750367 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose aerosolized pentamidine prophylaxis (300 mg once a month)
Number of subjects: 180
Study 8750367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month)
Number of subjects: 180
Study 8750367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (600 mg once a month)
Number of subjects: 180
Study 8750367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis
Number of subjects: 180
Study 2150073 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured glass ionomer liner (Espe, Seefeld/Oberbay, FRG)
Number of subjects: 99
Study 2150073 — intervention group
Group type: COMPARATOR
Intervention: Auto-cured glass ionomer cements (Vitrabond and another unspecified auto-cured cement)
Number of subjects: 99
Study 6995186 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg griseofulvin-FP daily for 8 weeks
Number of subjects: 44
Study 6995186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31950977 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 26828
Study 31950977 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2 Receptor Blockers (H2RBs)
Number of subjects: 26828
Study 31003878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication
Number of subjects: 159
Study 26990171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg BID
Number of subjects: 1300
Study 26990171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 22934930 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL prescription for hearing aids
Number of subjects: 218
Study 22934930 — intervention group
Group type: COMPARATOR
Intervention: DSL prescription for hearing aids
Number of subjects: 218
Study 22934930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' ratings of children's device usage
Number of subjects: 218
Study 22934930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' ratings of loudness discomfort
Number of subjects: 218
Study 22934930 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional performance within the first year of fitting
Number of subjects: 218
Study 22934930 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional disabilities and maternal education
Number of subjects: 218
Study 21473823 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hole exhalation valve
Number of subjects: 47
Study 21473823 — intervention group
Group type: COMPARATOR
Intervention: Plateau exhalation valve
Number of subjects: 47
Study 19969160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Number of subjects: 43
Study 19969160 — intervention group
Group type: COMPARATOR
Intervention: Blind injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Number of subjects: 43
Study 17675595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 14
Study 17675595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving LSVT)
Number of subjects: 14
Study 17675595 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (age-matched)
Number of subjects: 14
Study 14998846 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m2 (every 4 weeks)
Number of subjects: 509
Study 14998846 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 (every 3 weeks)
Number of subjects: 509
Study 14998846 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 509
Study 14998846 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD
Number of subjects: 509
Study 11685057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Eye Test (DET) modified fluorescein strip
Number of subjects: 75
Study 11685057 — intervention group
Group type: COMPARATOR
Intervention: Standard fluorescein strip (FUL-GLO)
Number of subjects: 75
Study 9532992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 500 mL saline over 30 minutes, then 500 mL at 30 drops per minute
Number of subjects: 0
Study 9532992 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 8018112 — intervention group
Group type: EXPERIMENTAL
Intervention: elaidic acid-rich diet
Number of subjects: 27
Study 8018112 — intervention group
Group type: COMPARATOR
Intervention: oleic acid diet
Number of subjects: 27
Study 2684660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg kg‐1 i.v. followed by a ketamine infusion of 2 mg kg‐1 h‐1
Number of subjects: 30
Study 2684660 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 30
Study 1031487 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training starting in the 10th or 14th week of pregnancy until term
Number of subjects: 62
Study 1031487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study 1031487 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 62
Study 31932495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 289
Study 30144380 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoTab (GT)
Number of subjects: 10
Study 30144380 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 10
Study 28070862 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 q4w 96 mg
Number of subjects: 87
Study 28070862 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 q4w 192 mg
Number of subjects: 87
Study 28070862 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine 8, 16, or 24 mg daily for 7 days
Number of subjects: 87
Study 28070862 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 q1w 16 mg
Number of subjects: 87
Study 28070862 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 q1w and q4w
Number of subjects: 87
Study 25706589 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher professional development program (workshops and in-classroom coaching)
Number of subjects: 1876
Study 24616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age-group (age >= 60)
Number of subjects: 140
Study 24616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients (disease time <= 7 days)
Number of subjects: 140
Study 24616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients (disease time > 7 days)
Number of subjects: 140
Study 24616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Total effective rate of senile sudden deafness patients
Number of subjects: 140
Study 24616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients with moderate deafness (hearing threshold < 55 dB)
Number of subjects: 140
Study 24616989 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger patients) with moderate deafness (hearing threshold < 55 dB)
Number of subjects: 140
Study 21638187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 25
Study 21638187 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 25
Study 19465880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine alone (n = 109)
Number of subjects: 327
Study 19465880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy alone (n = 111)
Number of subjects: 327
Study 19465880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (n = 107)
Number of subjects: 327
Study 16959450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine (EMLA patch 5%)
Number of subjects: 24
Study 16959450 — intervention group
Group type: COMPARATOR
Intervention: Control (no lidocaine-prilocaine)
Number of subjects: 24
Study 15465753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient interventions
Number of subjects: 40
Study 15465753 — intervention group
Group type: COMPARATOR
Intervention: Iron interventions
Number of subjects: 40
Study 15465753 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A interventions
Number of subjects: 40
Study 11740042 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement emphasising the sensory characteristics of Light cigarettes
Number of subjects: 1890
Study 11740042 — intervention group
Group type: COMPARATOR
Intervention: Advertisement emphasising the effect of vent blocking
Number of subjects: 1890
Study 11740042 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement framed as a PSA
Number of subjects: 1890
Study 11740042 — intervention group
Group type: COMPARATOR
Intervention: Advertisement promoting branded or unbranded NRT
Number of subjects: 1890
Study 9639787 — intervention group
Group type: EXPERIMENTAL
Intervention: MRGM with tail gas returned to circuit system (group M1)
Number of subjects: 51
Study 9639787 — intervention group
Group type: EXPERIMENTAL
Intervention: MRGM without tail gas returned (group M2)
Number of subjects: 51
Study 9639787 — intervention group
Group type: COMPARATOR
Intervention: No MRGM used (group C)
Number of subjects: 51
Study 8141714 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK) and subcutaneous heparin
Number of subjects: 0
Study 8141714 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK) and intravenous heparin
Number of subjects: 0
Study 8141714 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator (t‐PA) and intravenous heparin
Number of subjects: 0
Study 8141714 — intervention group
Group type: COMPARATOR
Intervention: Combination t‐PA and SK
Number of subjects: 0
Study 8141714 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated t‐PA regimen
Number of subjects: 0
Study 3099001 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 0
Study 3099001 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution
Number of subjects: 0
Study 29590007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Abiraterone (250 mg with a low-fat meal)
Number of subjects: 72
Study 29590007 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Abiraterone (1,000 mg fasting)
Number of subjects: 72
Study 29590007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Abiraterone
Number of subjects: 72
Study 29590007 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Abiraterone
Number of subjects: 72
Study 27421538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17β‐estradiol 1 mg/d
Number of subjects: 567
Study 27421538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 25161816 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy (psychodynamic)
Number of subjects: 326
Study 25161816 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychotherapy (psychodynamic or solution-focused)
Number of subjects: 326
Study 22531485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Lidocaine patch
Number of subjects: 30
Study 22531485 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study 20829500 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST; n = 9)
Number of subjects: 27
Study 20829500 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET; n = 10)
Number of subjects: 27
Study 20829500 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CT; n = 8)
Number of subjects: 27
Study 18755584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) based first-line chemotherapy
Number of subjects: 0
Study 15866596 — intervention group
Group type: COMPARATOR
Intervention: Rigid catheter (Tomcat; Kendall Sovereign, Mansfield, MA)
Number of subjects: 100
Study 15866596 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible catheter (Soft Pass; Cook, Spencer, IN)
Number of subjects: 100
Study 12532114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (mattress and pillow encasings)
Number of subjects: 60
Study 12532114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mattress and pillow encasings)
Number of subjects: 60
Study 12490967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg once daily for 16 weeks)
Number of subjects: 64
Study 9873260 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients with haemophilia A with inhibitors
Number of subjects: 52
Study 9873260 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients with haemophilia B
Number of subjects: 52
Study 9873260 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected patients with haemophilia A without inhibitors
Number of subjects: 52
Study 8138763 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of raised serum cholesterol concentration (> or = 6.5 mmol/l) after education intervention
Number of subjects: 495
Study 8138763 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of normal serum cholesterol concentration (< 5.2 mmol/l) after education intervention
Number of subjects: 495